Gedeon Richter Innovative Drugs RSFF

Improving the health of European citizens, increasing the competitiveness and boosting the innovative capacity of European health-related industries and businesses, while addressing global health issues including emerging epidemics, are some of the key objectives of the project. This research addresses not only an unmet medical need but also impacts the quality of life of certain patients. EIB financing of the project encourages research and technological development. In addition, the project would assist Hungary in improving its research capabilities.

Comments

Sector(s)

Industry

Proposed EIB finance (Approximate amount)

Up to EUR 150 million

Total cost (Approximate amount)

Up to EUR 382 million

Environmental aspects

R&D activities included in the project will not materially change current practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA), therefore, should not be required by the competent authorities as stated in the EU Directive 97/11 amended by Directive 2003/35.

Procurement

The promoter is a private company, not operating in the utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are in the best interest of the project and satisfactory to the Bank.

Status

Signed - 14/06/2011.

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. Therefore data provided on this page is indicative and cannot be considered to represent official EIB Policy (see also the Explanatory notes).

Projects

R&D involving development of new proprietary drugs for central nervous system indications in Budapest

E-mail

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments regarding the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.

Alternatively, EIB can also be contacted through its external offices.

Queries regarding details of a specific project, in particular when EIB loan is under appraisal, should be preferably addressed directly to project promoters.

Media enquiries

Media related enquiries can be addressed to the EIB Press Office. Please also visit our Press Corner.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged to EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero-tolerance against fraud and corruption

The EIB has a zero-tolerance policy on fraud or corruption. To report allegations of fraud or corruption in EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential, and are handled in line with EIB investigation procedures and the Anti-Fraud Policy.

EIB Transparency Policy

The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.

Guide to procurement

This Guide applies specifically to those components of a project identified for the Bank's financing.